Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationEur. Respir. J. 2002, 20(4):813-8
AbstractThis paper examines how pneumococcal type 6B polysaccharide conjugated to tetanus toxoid (Pn6B-TT) compares to a 23 valent pneumococcal vaccine (pneumococcal polysaccharide (PPS)-23) with respect to immunogenicity and serum opsonic activity in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD aged 55-75 yrs were vaccinated with Pn6B-TT (n=10) or with PPS-23 (n=9). Healthy young adults (HA) were vaccinated with Pn6B-TT as controls. Total antibodies to serotype 6B polysaccharide were measured by radioimmunoassay and immunoglobulin (Ig)G antibodies by enzyme-linked immunosorbent assay. Opsonic activity was measured by a phagocytosis assay using human neutrophils as effector cells. The patient groups were comparable by age, smoking history, lung function and use of steroids. COPD patients vaccinated with Pn6B-TT or PPS-23 showed an increase in IgG antibodies and a nonsignificant increase in opsonic activity. This was similar to the increase in IgG and opsonic activity seen in HA. There was a significant correlation between antibody levels and opsonic activity in COPD patients vaccinated both with Pn6B-TT and PPS-23. Pneumococcal antibodies have been shown to confer protection from infection. The results of the present study indicate that protective immunity can be expected in elderly chronic obstructive pulmonary disease patients vaccinated with conjugate vaccines.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.
- Authors: Vidarsson G, Sigurdardottir ST, Gudnason T, Kjartansson S, Kristinsson KG, Ingolfsdottir G, Jonsson S, Valdimarsson H, Schiffman G, Schneerson R, Jonsdottir I
- Issue date: 1998 Jun
- Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid.
- Authors: Sigurdardottir ST, Vidarsson G, Gudnason T, Kjartansson S, Kristinsson KG, Jonsson S, Valdimarsson H, Schiffman G, Schneerson R, Jonsdottir I
- Issue date: 1997 Jul
- Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.
- Authors: Richter MY, Jakobsen H, Birgisdottir A, Haeuw JF, Power UF, Del Giudice G, Bartoloni A, Jonsdottir I
- Issue date: 2004 Jan
- Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
- Authors: Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, Eskola J
- Issue date: 2004 Feb
- Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV.
- Authors: Talesnik E, Vial PA, Labarca J, Méndez C, Soza X
- Issue date: 1998 Dec 15